WO2021206589A1 - Composition for the prevention or treatment of endothelial dysfunction - Google Patents
Composition for the prevention or treatment of endothelial dysfunction Download PDFInfo
- Publication number
- WO2021206589A1 WO2021206589A1 PCT/RU2021/050094 RU2021050094W WO2021206589A1 WO 2021206589 A1 WO2021206589 A1 WO 2021206589A1 RU 2021050094 W RU2021050094 W RU 2021050094W WO 2021206589 A1 WO2021206589 A1 WO 2021206589A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- mammal
- disease
- treatment
- endothelial dysfunction
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 90
- 230000008694 endothelial dysfunction Effects 0.000 title claims description 85
- 206010048554 Endothelial dysfunction Diseases 0.000 title claims description 84
- 238000011282 treatment Methods 0.000 title claims description 51
- 230000002265 prevention Effects 0.000 title claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 44
- 241000124008 Mammalia Species 0.000 claims description 40
- 239000000413 hydrolysate Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241000237852 Mollusca Species 0.000 claims description 18
- 241000243818 Annelida Species 0.000 claims description 16
- 241000545744 Hirudinea Species 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 15
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 14
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 14
- 230000002378 acidificating effect Effects 0.000 claims description 13
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 13
- 238000007911 parenteral administration Methods 0.000 claims description 13
- 208000006673 asthma Diseases 0.000 claims description 12
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 8
- 230000003204 osmotic effect Effects 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 241000711573 Coronaviridae Species 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000002124 endocrine Effects 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 206010000050 Abdominal adhesions Diseases 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 3
- 206010014513 Embolism arterial Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 206010070538 Gestational hypertension Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 201000005624 HELLP Syndrome Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 3
- 208000034486 Multi-organ failure Diseases 0.000 claims description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000035056 Tick-Borne disease Diseases 0.000 claims description 3
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims description 3
- 201000004810 Vascular dementia Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 206010069351 acute lung injury Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 201000009267 bronchiectasis Diseases 0.000 claims description 3
- 208000015669 capillary disease Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 3
- 230000002631 hypothermal effect Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 201000006334 interstitial nephritis Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 claims description 3
- 201000001474 proteinuria Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000016523 tick-borne infectious disease Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 241001678559 COVID-19 virus Species 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 63
- 210000003038 endothelium Anatomy 0.000 description 37
- 230000000694 effects Effects 0.000 description 24
- 210000002889 endothelial cell Anatomy 0.000 description 21
- 230000002792 vascular Effects 0.000 description 18
- 229960003753 nitric oxide Drugs 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 11
- 230000006735 deficit Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 229960001123 epoprostenol Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000003511 endothelial effect Effects 0.000 description 8
- 230000006442 vascular tone Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 6
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 5
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 5
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 5
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- 102400000345 Angiotensin-2 Human genes 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000005526 vasoconstrictor agent Substances 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102400000686 Endothelin-1 Human genes 0.000 description 3
- 101800004490 Endothelin-1 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- 229930064664 L-arginine Natural products 0.000 description 3
- 235000014852 L-arginine Nutrition 0.000 description 3
- 108010079274 Thrombomodulin Proteins 0.000 description 3
- 102100026966 Thrombomodulin Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000003954 umbilical cord Anatomy 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 230000001457 vasomotor Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 description 2
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 2
- 102000014469 Guanylate cyclase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 241000237503 Pectinidae Species 0.000 description 2
- 241000490567 Pinctada Species 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 241000196381 Teredinidae Species 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 241000512272 Tridacna Species 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- -1 belaprost Chemical compound 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 2
- 210000004692 intercellular junction Anatomy 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000003558 thrombophilic effect Effects 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102000004149 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 241000217381 Anodonta Species 0.000 description 1
- 241000607342 Arctica islandica Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241001416153 Bos grunniens Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 101100086436 Caenorhabditis elegans rap-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102100021242 Dymeclin Human genes 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102000009839 Endothelial Protein C Receptor Human genes 0.000 description 1
- 108010009900 Endothelial Protein C Receptor Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 108010016193 MIGI-K Proteins 0.000 description 1
- 241001508691 Martes zibellina Species 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 description 1
- 101100523604 Mus musculus Rassf5 gene Proteins 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 241000237525 Mytilidae Species 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- FQWRAVYMZULPNK-UHFFFAOYSA-N N(5)-[(Z)-amino(hydroxyimino)methyl]ornithine Chemical compound OC(=O)C(N)CCCNC(N)=NO FQWRAVYMZULPNK-UHFFFAOYSA-N 0.000 description 1
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 101100420081 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rps-0 gene Proteins 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229940123921 Nitric oxide synthase inhibitor Drugs 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000879835 Panopea Species 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000545760 Unio Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- BEVHTVRRVVEMEF-UHFFFAOYSA-N [6'-acetyloxy-4-amino-2',7'-difluoro-5-(methylamino)-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl] acetate Chemical compound C12=CC(F)=C(OC(C)=O)C=C2OC2=CC(OC(C)=O)=C(F)C=C2C21OC(=O)C1=C(N)C(NC)=CC=C21 BEVHTVRRVVEMEF-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004323 caveolae Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910001613 cyprine Inorganic materials 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- KWDSFGYQALRPMG-UHFFFAOYSA-N delta-N-Hydroxy-L-orginin Natural products OC(=O)C(N)CCCN(O)C(N)=N KWDSFGYQALRPMG-UHFFFAOYSA-N 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 210000004954 endothelial membrane Anatomy 0.000 description 1
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 229960002240 iloprost Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000020964 regulation of blood coagulation Effects 0.000 description 1
- 230000009076 regulation of hemostasis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940032362 superoxide dismutase Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 229940105295 ventavis Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Definitions
- the present invention relates to the field of veterinary and medicine.
- the present invention relates to a use of a composition based on a hydrolysate obtained from one or more natural biological resources selected from the group including bivalve mollusks, annelids, and leeches, for the prevention or treatment of endothelial dysfunction (ED) and/or an ED-related disease or condition in a mammal in need of such treatment or prevention.
- ED endothelial dysfunction
- the present invention also relates to methods for the prevention and treatment of ED and/or an ED-related condition or disease using the above composition.
- Endothelium is a monolayer sheet of squamous cells having mesenchymal origin which lines the inner surface of blood and lymphatic vessels, cardiac cavities.
- the endothelium is an active endocrine organ diffusely distributed throughout all tissues.
- the endothelium forms the inner lining of blood vessels separating blood flow from the deeper layers of the vascular wall. It is a continuous monolayer of l-6xl0 13 endothelial cells which form a tissue weighting 1.5-2.0 kg and having a total surface area of about 900 m 2 in humans.
- the endothelium continuously produces an enormous number of crucial biologically active substances thus being a giant paracrine organ distributed across the entire area of the human body.
- endothelial cells include, inter alia, the following: regulation of vascular tone (vasoconstriction and vasodilation); regulation of hemostasis (thrombogenicity and atrombogenicity of the vascular wall); angiogenesis (formation of new blood vessels); participation in immune reactions (activation of leukocyte adhesion, production of cytokines) including an essential barrier immune function.
- the endothelium is known to be able to produce biologically active substances (BAS) which maintain the tone of underlying vascular smooth muscle cells (SMC), preserve non-adhesiveness of intima, and influence inflammatory and immune mechanisms in the vascular wall.
- BAS biologically active substances
- SMC vascular smooth muscle cells
- endothelial cells perform numerous functions in a tight relationship with SMCs. Therefore, the regulation of vascular tone is considerably associated with BAS synthesis by endothelial cells.
- Nitric oxide is the main factor controlling the vascular tone; it can regulate and distribute blood flow in various vascular pools by changing the diameter of both large and small arteries and arterioles via the stimulation of guanylate cyclase and an increase in the intracellular cGMP concentration.
- nitric oxide has many additional unique functions what makes it the main factor in antiatherogenesis.
- NO as a universal signaling molecule, suppresses platelet adhesion to the endothelium and their aggregation, possesses anti-inflammatory properties, regulates the synthesis and breakdown of the extracellular matrix, prevents cell migration and proliferation, and controls gene transcription.
- NO acts as a secondary messenger for many growth factors, peptides, blood coagulation factors and hormones, and also facilitates transendothelial migration of leukocytes and endothelial cell precursors.
- the endothelium is involved in the regulation of blood coagulation (formation of fibrinolysis activators and inhibitors, pro- and antithrombotic factors) and vascular wall permeability (free radicals, protein kinase C).
- the endothelium is capable to regulate adhesive properties of the vascular wall (expression of adhesion molecules - ICAMs, YCAMs, as well as E- and P-selectins).
- P- and E-selectins are involved in leukocyte rolling, whereas ICAMs and VCAMs are responsible for their adhesion through the interaction with relevant ligands for white blood cells.
- ED Since ED is associated with an imbalance between the production of vasodilators and vasoconstrictors, thrombogenic and atrombogenic factors, angiogenic substances and their inhibitors, it is subdivided into vasomotor, thrombophilic, adhesive and angiogenic forms. An increased adhesiveness of the endothelium and uncontrolled stopping of leukocytes underlie the adhesive ED form and play an important role in pathogenesis of inflammation in atherosclerosis and other pathological processes.
- thrombophilic ED form is mediated by an impaired ratio between factors which induce platelet adhesion and aggregation, thrombogenesis, suppress fibrinolysis (von Willebrand factor, platelet-activating factor, thromboxane A2, tissue factor, etc.), and atrombogenic substances (NO, prostacyclin, thrombomodulin, t-PA, etc.) with a predominance of the former ones.
- a significant decrease in vascular thromboresistance has been recorded in atherosclerosis, hypertension, diabetes mellitus, and tumor diseases.
- DIC chronic disseminated intravascular coagulation
- the angiogenic ED form is associated with pathological angiogenesis - an excessive activity of VEGF-A and other growth factors, and impairment in the system of angiogenesis regulators (angiopoietins, angiostatin, etc.).
- vasomotor ED form is mediated by a defect in endothelial vasoactive substance performance and plays an important role in mechanisms of both a systemic increase in blood pressure and local angiospasm.
- a change in endothelium-dependent vascular relaxation occurs for many reasons: decreased NO production, enhanced inactivation of vasodilators, weakened diffusion of NO to the underlying smooth muscle cells, reduced availability of L-arginine deposits, a precursor of NO, increased degradation of NO by free oxygen radicals, and increased production of vasoconstrictors.
- ED also includes accelerated desquamation of capillary endothelium, weakened intercellular junctions, impaired protein synthesis, as well as impaired expression and formation of adhesive glycoproteins on endothelial cells. This facilitates the attachment of monocytes and leukocytes, as well as their migration across the basement membrane.
- Endothelial cells of either large or small vessels are insulin-independent cells. Therefore, under hyperglycemic conditions in diabetes mellitus glucose can freely enter into endothelial cells producing pathological biochemical reactions inside the cells which are an important cause of ED. Hyperglycemia delays the replication of endothelial cells and promotes cell death by increasing oxidative processes and glycation. ED is an integrated syndrome of insulin resistance, with exacerbation thereof, increases vascular reactivity, and provokes cardiovascular disorders.
- ED is one of the earliest signs of vascular lesions in patients with DM and could be detected at the initial stages of the disease, even before the appearance of atherosclerotic plaques; endothelial dysfunction remains to be a concern at the later stages of atherosclerotic lesion because impairments of endothelium-dependent vascular relaxation and increased adhesiveness of the endothelial lining could provoke a constriction, and the formation and growth of a plaque followed by its rupture. Accordingly, ED also manifests as the impairment of vascular tone regulation and, as a consequence, central and peripheral hemodynamics. The second consequence is the impairment of substance transport through the vascular wall. Lipid accumulation in the vascular wall and their involvement in atherogenesis should be considered as one of the main manifestations of that.
- Vitamin C was shown to protect the endothelium against superoxide radical effects that prevents lipid oxidation, neutrophil adhesion and ultimately the development of endothelial dysfunction [Taddei S., Virdis A., Ghiadoni L, Magagna A., Salvetti A. Vitamin C improvesendo the lium-dependent vasodilation byrestoring nitricoxide activity in essential hypertension. Circulation. 1998; 97:2222-2229 ].
- Vitamin E also has a protective effect on the endothelium in hypercholesterolemia but its use in diabetes mellitus produces an opposite effect [ Economides P.A, Khaodhiar L, Caselli A, Caballero A.E, Keenan H, Bursell S.E., King G.L., Johnstone M.T., Horton E.S., Veves A. The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. Diabetes. 2005; 54:204-211 ⁇ .
- N-acetyl cysteine influences the production of glutathione which is the main endogenous antioxidant protecting the endothelium against free radicals and the damaging effect of various cytokines, such as tumor necrosis factor alpha [ Bourraindeloup M., Adamy C, Candiani G., Cailleret M., Bourin M.C., Badoual T, Su J.B., Adubeiro S., Roudot-Thoraval F., Dubois-Rande J.L.
- N-acetylcysteine treatment normalizes serum tumor necrosis factor-alpha level and hinders the progression of cardiac injury in hypertensive rats. Circulation.
- N-acetylcysteine regulates the expression of metalloproteinases which cleave intercellular junction proteins of the endothelium that significantly contributes to the development of endothelial dysfunction
- metalloproteinases which cleave intercellular junction proteins of the endothelium that significantly contributes to the development of endothelial dysfunction
- Prostaglandins are endogenous biologically active substances of lipid nature synthesized in almost all cells of the body. While prostaglandin E2 is involved in the development of inflammation, prostacyclin and some other prostaglandins have a vasodilatory effect, and also prevent platelet aggregation with endothelial cells. Prostacyclin and its synthetic analogs (iloprost, belaprost, ventavis, etc.) are successfully being used to reduce the permeability of endothelium in combined treatment of ischemia-reperfusion [H. Schutte, A.Lockinger, W.Seeger, et al.
- Aerosolized PGE1, PGI2 and nitroprusside protect against vascular leakage in lung ischaemia-reperfusion. Eur. Respir. J., 2001; 18:15-22] In endothelial cells, these substances are thought to induce the adenylate cyclase mechanism which reinforces the endothelial barrier by forming new or strengthening the already existing intercellular adhesion complexes.
- prostacyclin was shown to reduce endothelial permeability in LPS-induced inflammation in mice by activating Rapl protein, one of the last participants in the adenylate cyclase pathway [Birukova A.A., Meng F.,Tian Y., Meliton A., Sarich N, Quilliam LA., Birukov K.G. Prostacyclinpost-treatmentimproves LPS- induce dacutelung in juryandendo the lialbarrier recovery via Rap 1. BiochimBiophysActa.
- an action of prostacyclin can be blocked by other cytokines leading to opposite effects, i.e., enhanced endothelial dysfunction [Blanco-Rivero J., Cachofeiro V., Lahera V., Aras-Lopez R, -Marquez-Rodas /., Salaices M., Xavier F.E., Ferrer M., Balfagon G. Participation of prostacyclininendo the lialdysfunction induced byaldosterone in normotensive and hypertensiverats.
- Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor (AR) blockers are also antihypertensive agents and exert a protective action on the endothelium.
- Angiotensin II is a protein hormone synthesized from an inactive precursor angiotensin I by ACE. Angiotensin II has a strong vasoconstrictor effect and for this reason ACE is targeted by many drugs, such as perindopril, fosinopril, losartan, etc.
- ACE inhibitors were observed amongst others: increased expression of NO-synthase in ischemia-reperfusion [B.Gemici, R.Tan, G.Ongut, V.N. Izgut-Uysal Expressions of induciblenitricoxidesynthase and cyclooxygenase- 2 ingastricis chemia - reperfusion: role of angiotensinll. J SurgRes, 2010; 161:126-133 ], decreased apoptosis of endothelial cells, decreased concentrations of tumor necrosis factor alpha and other pro-inflammatory cytokines ⁇ A.M.
- ACE inhibitors and angiotensin receptor blockers were also shown to have a beneficial effect on the endothelium in coronary heart disease and hypercholesterolemia [ B.Hornig , U.Landmesser, C.Kohler, D.Ahlersmann, S.Spiekermann, A.Christoph, Comparative effect of aceinhibition and angiotensin II type 1 recept or antagonism on bioavailability of nitricoxidein patients with coronaryarterydisease: role of super oxidedismutase. Circulation, 2001; 103:799-805 ].
- An object of the present invention was to provide a more effective method for the prevention and treatment of ED and/or ED-related conditions.
- patent RU 2526826 discloses the composition for parenteral administration comprising a hydrolysate based on biological raw materials obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches, and water, and having a broad spectrum of action and properties.
- the present disclosure provides a use of a composition based on a hydrolysate obtained from one or more biological resources selected from the group including bivalve mollusks, annelids, and leeches, for the prevention or treatment of ED, as well as diseases or conditions accompanied by or related to ED, in a mammal in need of such prevention or treatment.
- Said composition comprises a wide range of essential amino acids, melanoidins acting as antioxidants, regulatory peptides, saturated and unsaturated fatty acids, macro- and microelements in a balanced native natural ratio, and, inter alia, has an immunomodulating property and is employed for therapeutic and/or prophylactic purposes in veterinary and medicine.
- the present invention provides a use of a composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of endothelial dysfunction in a mammal in need of such treatment or prevention.
- the present invention provides a use of a composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of endothelial dysfunction and/or a disease or condition related to endothelial dysfunction in a mammal in need of such treatment or prevention.
- the present invention provides a use of a composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of a disease or condition with concomitant endothelial dysfunction in a mammal in need of such treatment or prevention.
- the present invention relates to the composition for use according to any of applications described above.
- the present invention provides a method for the treatment or prevention of endothelial dysfunction in a mammal in need of such treatment or prevention, comprising parenteral administration of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, to said mammal.
- the present invention provides a method for the treatment of endothelial dysfunction and/or a disease or condition related to endothelial dysfunction in a mammal in need of such treatment or prevention, comprising parenteral administration of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, to said mammal.
- the present invention provides a method for the treatment of a disease or condition with concomitant endothelial dysfunction in a mammal in need of such treatment or prevention, comprising parenteral administration of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, to said mammal.
- Fig. 1 shows study data demonstrating the effect of enhancing eNOS activity in human umbilical cord vein endothelial cells (HUVECs) by using the composition according to the present invention.
- Fig. 2 shows study data demonstrating the effect of reducing the expression of adhesion molecules VCAM and ICAM in human umbilical cord vein endothelial cells (HUVECs) by using the composition according to the present invention.
- Fig. 3 shows study data demonstrating the effect of reducing iNOS activity in the cell culture from peritoneal lavage of mice.
- a disturbance of endothelium functions is one of universal mechanisms of pathogenesis of many diseases including common ones such as atherosclerosis, hypertension, and diabetes mellitus.
- Dysfunction of the endothelium or endothelial dysfunction (ED) plays a role in the development of thrombosis, neoangiogenesis, vascular remodeling, and intravascular activation of platelets and leukocytes.
- the predominant impairment of one or another function of the endothelium depends on the localization of pathological processes, prevalence of one or other of inflammatory mediators, and presence of hemodynamic shifts.
- An implication of the endothelium in the regulation of vasomotor reactions, hemostasis, angiogenesis, vascular-tissue migration of leukocytes was the most comprehensively studied.
- Endothelial dysfunction is one of the most important pathogenetic mechanisms of many cardiovascular diseases.
- endothelial dysfunction could cause vasoconstriction, increased clotting and enhanced adhesion of leukocytes to the endothelium which is accompanied by the impairment of regional blood circulation and microcirculation.
- Endothelial dysfunction can be caused by the following factors: genetic features; age-related changes; dyslipoproteinemia (hypercholesterolemia); hypercytokinemia; hyperhomocysteinemia; hyperglycemia; hemodynamic factor (hypertension, ischemia, venous stasis); endogenous intoxications (renal failure, hepatic failure, pancreatitis, etc ); exogenous intoxications (smoking, etc.)
- endothelial dysfunction represents a state of the endothelium with insufficient production of nitric oxide (NO). Since nitric oxide is involved in the regulation of almost all functions of the endothelium (regulation of vascular tone, vascular thromboresistance, regulation of leukocyte adhesion and vascular permeability), and additionally is the factor most sensitive to a lesion, this insight into endothelial dysfunction is quite correct, although not entirely comprehensive. The most important factor interfering nitric oxide formation and/or bioavailability is an excessive generation of reactive oxygen species observed in many diseases.
- NO nitric oxide
- One of the methods for evaluating the severity of ED is the assessment of various substances, which are produced in the endothelium, in the blood.
- various substances which are produced in the endothelium, in the blood.
- there are techniques for determining in the blood almost all known substances produced in the endothelium; however, not all indicators have the same diagnostic value, since a significant portion of ED markers is produced not only in the endothelium but in other cells as well.
- the degree of specificity the most considerable are, in particular, nitric oxide, prostacyclin, endothelin-1, ICAM-1, VCAM-1, E- selectin, annexin-II, thrombomodulin and others.
- nitric oxide and prostacyclin are constantly synthesized in the endothelium, and the disturbance of their synthesis or decrease in bioavailability may indicate the presence of lesions in the endothelium.
- inducible nitric oxide synthase and cyclooxygenase-2 are generated in the endothelium that leads to a significant elevation in the production of NO and prostacyclin.
- factors such as endothelin-1, ICAM-1, VCAM-1, and E-selectin are virtually not synthesized; however, their concentrations sharply rise upon activation of the endothelium.
- Factors such as intracellular proteins (tissue factor, annexin-V) or endothelial membrane receptors (thrombomodulin, protein C receptor) are observed in the blood upon damage of the endothelium or apoptosis.
- nitric oxide (NO) is involved in very different bioregulatory effects of the vascular process, a decline in its level in endothelial cells (ECs), due to various factors, leads to significant changes in their functions and the circulatory system in general. Impairments are manifested (Shiffrin E.L., 2001; Egashira K., 2002; Feletou M., 2006; Cooke J.P., 2003, Endemann D.H., 2004, Zolotova I.V. (3oToea H.B.), 2000; Markov K.M.
- Nitric oxide is synthesized in the endothelium (by isoforms of the enzyme NO-synthase: 2 of them are constitutive - endothelial (eNOS) and neuronal and 1 is inducible (iNOS)) through the reaction of amino acid L-arginine, with the involvement of molecular oxygen.
- a catalyst is the enzyme NO-synthase.
- the reaction can be schematically depicted as follows: L-arginine + 0 2 ®L- citrulline + NO.
- Constitutive endothelial NO-synthase (eNOS) is involved in the cardiovascular system regulation.
- Nitric oxide is synthesized stepwise with the formation of intermediate N- hydroxy-L-arginine.
- nitric oxide is released from endothelial cells and diffuses into the deeper myocytes of the vascular walls.
- NO vascular myocytes
- guanylate cyclase that leads to an increase in the content of 3,5-cyclic guanosine monophosphate
- these processes provoke a decrease in the calcium concentration resulting in relaxation of smooth muscle cells and vasodilation [Cavelin, caveolae and endothelium cell function. / Frank P.O., Woodman S.E., Park D.S., Lisanii M.P. // ArteriosclerThrombVaseBiol 2003; 23:1161-1168., Zotova, I.V.
- endothelial NO-synthase eNOS
- Endogenous eNOS inhibitors are the first in a series of factors leading to this, for example, ADMA [Association analysis of CA repeat polymorphism of the endothelial nitric synthase gene to essential hypertension in Japanese. NakaymaT., Soma J., Takahashi J. el al. Clin Genet 1997; 51:26-30., Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
- ADMA Asymmetric dimethylarginine
- composition obtained on the basis of hydrolysate from biological resources and previously described in patent RU 2526826 may be used to increase eNOS activity and reduce iNOS activity in the body of a mammal in need of prevention or treatment of endothelial dysfunction and/or an ED-related condition or disease, as well as to increase nitric oxide concentrations, decrease adhesion molecules VCAM-1 and ICAM-1 in endothelial cells of said mammal, suggesting that said composition may be effectively employed for treating a number of pathological conditions and diseases related to ED.
- the present invention provides a use of a composition
- a composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of ED and/or an ED-related disease or condition in a mammal in need of such treatment or prevention.
- Said hydrolysate is a product of hydrolysis of biological raw materials.
- biological resources are selected from the group including bivalve mollusks, crustaceans, annelids, and leeches.
- Said biological resources allow for obtaining the hydrolysate with a balanced chemical composition
- a balanced chemical composition comprising, inter alia, a wide range of amino acids including essential amino acids, saturated and unsaturated fatty acids, melanoidins, carbohydrates, micro- and macroelements, which serves as the basis for manufacturing the composition allowing to achieve the desired therapeutic and prophylactic effect when administered parenterally to a mammal in need of such treatment or prevention.
- said biological raw materials are bivalve mollusks including swan mussel ( Anodonta ), pearl shell ( Unio ), oysters ( Ostreidae ), mytilids ( Mytilidae ), tridacna ( Tridacna ), pearl oysters ( Pinctada ), scallops (. Pectinidae ), shipworms ( Teredinidae ), goeduck (Panopea abrnpta ), Icelandic cyprine (Arctica Islandica) and other commercial types of mollusks.
- hydrolysate obtained from biological resources in the context of this specification is understood a liquid solution obtained by enzymatic and/or acidic hydrolysis of the biological resources described above.
- Various methods for conducting hydrolysis of biological resources are known in the art and can be selected by a person skilled in the art when implementing the present invention.
- patents RU 2134523, RU 2374892, RU 5042669, RU 2090084, RU 2066105, RU 2134523, RU 2319409 describe various conditions for conducting the hydrolysis of protein raw materials suitable according to the present invention.
- hydrolysates from mytilids including but not limiting to MIDEL («MH3 ⁇ 43JI»), MIGI-K ( «MHG ⁇ -K»), may be used as an initial hydrolysate for producing the composition.
- the dilution factor of solution obtained immediately after aqueous hydrolysis is determined empirically by a person skilled in the art such that the amount of mineral salts, in particular sodium chloride, in the final product (composition) does not exceed the total blood salinity of a mammal to which the composition is to be administered.
- the amount of hydrolysate in the composition is 2 to 8 wt.%, preferably 3 to 7 wt.%, more preferably 4 to 6%, most preferably about 5 wt.%.
- the amount of hydrolysate may be 1 to 4 wt.%, 1 to 3 wt.%, 1 to 2 wt.%, 6 to 9 wt.%, 7 to 9 wt.% and 8 to 9 wt.%.
- the remaining portion is water and optionally auxiliary ingredients, e.g. glucose.
- the amount of hydrolysate does not typically exceed 10 wt.% of the composition, as otherwise the composition will not be suitable for certain types of parenteral administration, in particular, injectional administration, due to the presence of high salt concentration therein.
- the weight fraction of hydrolysate is typically at least 1 wt.% to provide the composition with sufficient amount of components for achieving a desired effect in treating and/or preventing ED and ED-related diseases and conditions.
- the final dilution factor of hydrolysate will be defined by specific conditions for conducting the hydrolysis of initial biological raw materials and the need for dilution in general, depending on the method of administration of the composition, a species of mammal and other conditions.
- said composition is characterized by the weight fraction of amine nitrogen of at least 0.01 wt.%.
- the weight fraction of amine nitrogen is 0.01 to 0.5 wt.%. More preferably, the weight fraction of amine nitrogen is 0.05 to 0.5 wt%, most preferably 0.02 to 0.1 wt.%.
- the value of weight fraction of amine nitrogen characterizes the conversion rate for hydrolysis of biological resources and represents a factor which allows for assessing the completeness of this process. This characteristic serves as an indirect indicator of the presence of necessary components within the final composition for parenteral administration when using biological resources in accordance with this specification.
- the provided composition has pH value 4 to 7, preferably 5 to 7, most preferably 5.5 to 6.5.
- the pH value within the above range indicates a sufficient degree of hydrolysate neutralization, as well as the possibility of using said composition for therapeutic and/or prophylactic purposes in mammals.
- the provided composition has the weight fraction of solids 0.5 to 5 wt.%, preferably 1 to 3 wt.%, most preferably 1.2 to 1.8 wt.%.
- disease or condition related to endothelial dysfunction is understood the condition and disease which development or pathogenesis is related to the impairment of normal functioning of endothelial cell layer or its damage.
- the course of said conditions or diseases is accompanied by the impairment of normal functioning of endothelial cell layer or its damage, or by diagnosed endothelial dysfunction.
- disease or condition in the context of this specification is understood one of diseases or conditions selected from the group including: atherosclerosis, hypertension, coronary failure, myocardial infarction, insulin resistance, diabetes mellitus, renal failure, hereditary and acquired metabolic disorders (dyslipidemia, etc.), endocrine age-related disorders, respiratory pulmonary pathologies (asthma), abdominal adhesions, major surgeries, hypothermia, bums (thermal and chemical), extensive blood loss, heart attack, stroke, sepsis, septic shock, cancers, tick-borne diseases, multiple organ failure, vascular dementia,
- diseases or conditions selected from the group including: atherosclerosis, hypertension, coronary failure, myocardial infarction, insulin resistance, diabetes mellitus, renal failure, hereditary and acquired metabolic disorders (dyslipidemia, etc.), endocrine age-related disorders, respiratory pulmonary pathologies (asthma), abdominal adhesions, major surgeries, hypothermia, bums (thermal and
- Parkinson's disease autoimmune diseases, senility, asthma, acute lung injury, acute respiratory distress syndrome,
- Middle East respiratory syndrome chronic obstructive pulmonary disease
- viral infections including infections caused by coronaviruses, including SARS-CoV, SARS- CoV-2, preeclampsy, eclampsy, pregnancy-induced hypertension with significant proteinuria, emphysema, asthma, asthmatic condition, bronchiectasis peripheral vascular diseases, arterial embolism and thrombosis, capillary diseases,
- an ED-related condition may be any disease specified in the International Classification of Diseases (ICD 10) in sections C22 (Malignant neoplasm of liver and intrahepatic bile ducts), C26 (Malignant neoplasm of other and ill-defined digestive organs) and T22 (Thermal and chemical body burns), as well as other diseases disclosed in this specification.
- ICD 10 International Classification of Diseases
- the present invention alternatively provides the use of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of any disease or condition from the group above with concomitant endothelial dysfunction, in a mammal in need of such treatment or prevention.
- the present invention provides the use of the composition disclosed in this specification for the prevention or treatment of endothelial dysfunction.
- This embodiment includes the treatment of endothelial dysfunction, regardless of the presence or absence of any concomitant diseases or conditions specified above.
- the composition is administered “parenterally” which means any methods of administration, excluding entry of the provided composition into the body of a mammal in need thereof through the gastrointestinal tract.
- parenteral administration may be injectional, intranasal, subconjunctival administration of the composition in the form of solutions, the use of solutions in the form of gargles, rinsing, soaking treatments, wraps, as well as applying the composition onto affected surface in the form of creams, ointments, gels on a hydrophilic base.
- the composition is additionally sterilized and represents the composition for injectional administration.
- Said injectional administration can be carried out intravenously (i.v.), intradermally, subcutaneously (s.c.), intramuscularly (i.m.) or intraosseously (i.o.), wherein said administration can be carried out in a continuous (permanent) mode using a dropper, various drug dispensers, including osmotic pumps, pumps (similar to insulin pumps), or another suitable dispensing device.
- the mammal may be an animal or a human.
- the animal may be a farm animal selected from the group including a cow, buffalo, yak, deer, pig, goat, sheep, rabbit, horse, donkey, camel, lama, sable, fox, mink, ferret, etc., or the animal may be a domestic pet, e.g., such as dog, cat, rat, hamster, guinea pig, etc., or the animal may be a wild animal.
- the animal is a mouse.
- the composition is administered to said mammal for 1-5 days at a dosage of 0.2 to 6.0 pil ⁇ k g/h
- this administration may be carried out by continuous parenteral administration, in particular subcutaneous, intravenous or intramuscular injection using a suitable dosing device, for example, dropper, pump (similar to insulin pump), osmotic pump.
- a suitable dosing device for example, dropper, pump (similar to insulin pump), osmotic pump.
- This dosage was found to be effective in treating/eliminating ED and ED-related diseases and diseases.
- a skilled person in medicine or veterinary will be able to select empirically a necessary specific dosage taking into account characteristics of patient's body, disease severity and other conditions.
- the composition is administered to said mammal at a dosage of 10- 400 pl/h for 1-5 days.
- the administration may optionally be carried out by continuous parenteral administration, in particular subcutaneous, intravenous or intramuscular injection using a suitable dosing device, for example, dropper, pump, or osmotic pump.
- the composition is administered continuously (permanently) into the body of a mammal in need thereof using an osmotic pump, pump or dropper.
- composition is administered to said mammal for 7-10 days.
- the use of said composition may include concurrent administration of said composition and means of conventional combination therapy for the prevention or treatment/elimination of ED in a patient in need thereof.
- the present invention provides a method for the treatment/elimination of ED and/or ED-related diseases and conditions in a mammal in need of such treatment or prevention, comprising parenteral administration of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, to said mammal.
- the present invention alternatively provides a method for the prevention or treatment of the disease or condition from the group of conditions or diseases disclosed in this specification with concomitant endothelial dysfunction, in a mammal in need of such treatment or prevention, using the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water.
- the present invention provides a method for treating endothelial dysfunction using the composition disclosed in this specification. This embodiment includes the treatment of endothelial dysfunction, regardless of the presence or absence of any of concomitant diseases or conditions related to endothelial dysfunction.
- the composition is administered to said mammal for 1-5 days at a dosage of 0.2 to 6.0 pl * kg/h.
- this administration may be carried out by continuous parenteral administration, in particular subcutaneous, intravenous or intramuscular injection using a suitable dosing device, e.g., dropper, pump or osmotic pump.
- the composition is administered to said mammal at a dosage of 10-400 m ⁇ /h for 1-5 days
- said administration may optionally be carried out by continuous parenteral administration, in particular subcutaneous, intravenous or intramuscular injection using a suitable dosing device, e.g., dropper, pump or osmotic pump.
- the provided method of treatment comprises the use of the composition intended for injectional administration which is administered to said mammal for 7-10 days.
- the provided method of treatment comprises the use of the composition intended for injectional administration and may further comprise the repeated course which is carried out in 1-2 days upon completion of the first one.
- the provided method of treatment comprises the use of the composition intended for injectional administration, and may comprise the concurrent use of said composition and means of conventional combination therapy for the prevention or treatment of ED and/or ED- related diseases and conditions in a patient in need thereof.
- EXAMPLE 1 Effect of the composition on eNOS activity
- human umbilical cord vein endothelial cells (HUVECs) were added to 12-well plates (Sarstedt) and cultured until a confluent monolayer formed.
- the composition containing 5% wt. hydrolysate from mytilids and water was then added at various dilutions and incubated for 72 h at 37°C in humidified atmosphere with 5% CO2.
- the DAF-FM DA dye (Invitrogen) was added at a concentration of 1 mM and incubated for 1 h.
- the monolayer was disintegrated and cells were fixed with 4% formaldehyde solution (Sigma). Sample measurements were conducted using NaviosTM flow cytometer (Beckman Coulter).
- Fig. 1 The study results are shown in Fig. 1.
- the composition based on the hydrolysate from mytilids was shown to activate eNOS and increase the production of NO by almost 3 times.
- VCAM-1 CD 106
- ICAM-1 CD54
- HUVECs were added to 24-well plates (Sarstedt) at a concentration of 150,000 cells per ml.
- the composition containing 5% wt. hydrolysate from mytilids and water was then added for 72 hours at different dilutions.
- TNFa was added to wells at a concentration of 25 U/ml 24 hours before the end of incubation.
- the expression of surface molecules was assessed by flow cytometry using anti- CD106PE (cat. #PN A66085) and anti-CD54PE (cat. #PN IM1239U) monoclonal antibodies.
- Cell suspensions were stained according to manufacturer's recommendation.
- necrosis level cell suspension was additionally stained with the DNA-binding dye DAPI (Invitrogen) at a concentration of 1 mg/ml. Samples were analyzed using NaviosTM flow cytometer (Beckman Coulter).
- the study results are shown in Fig. 2.
- the obtained results indicate that the composition based on the hydrolysate from mytilids reduces the expression of VCAM-1 on HUVECs after induction with TNF-alphaby 3.6 times.
- EXAMPLE 3 Effect of the composition on iNOS activity.
- mice peritoneal lavage cell culture was used.
- CBA/BALB (FI) mice from the “Rappolovo” nursery were kept under conditions of unlimited access to food and water in accordance with accepted ethical standards.
- Peritoneal lavage cells were obtained by washing the abdominal cavity of mice with sterile Hanks solution.
- LPS Esherichia coli 055 :B5, Sigma-Aldrich, Germany
- the composition containing 5% wt. hydrolysate from mytilids and water were added to wells.
- Spectrometric analysis was conducted at a wavelength of 540 nm (Microplate reader, Model 680, Bio-Rad). Nitrite and nitrate concentrations in experimental samples were determined mathematically in accordance with linear fitting by the method of least squares based on the calibration curve constructed using sodium nitrite (NaNCh) solution with known concentration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The use of a composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of endothelial dysfunction (ED) and/or an ED-related disease or condition in a mammal in need of such treatment or prevention.
Description
COMPOSITION FOR THE PREVENTION OR TREATMENT OF ENDOTHELIAL DYSFUNCTION
FIELD OF THE INVENTION
The present invention relates to the field of veterinary and medicine. In particular, the present invention relates to a use of a composition based on a hydrolysate obtained from one or more natural biological resources selected from the group including bivalve mollusks, annelids, and leeches, for the prevention or treatment of endothelial dysfunction (ED) and/or an ED-related disease or condition in a mammal in need of such treatment or prevention. The present invention also relates to methods for the prevention and treatment of ED and/or an ED-related condition or disease using the above composition.
BACKGROUND OF THE INVENTION
Endothelium is a monolayer sheet of squamous cells having mesenchymal origin which lines the inner surface of blood and lymphatic vessels, cardiac cavities. In light of contemporary concepts, the endothelium is an active endocrine organ diffusely distributed throughout all tissues. The endothelium forms the inner lining of blood vessels separating blood flow from the deeper layers of the vascular wall. It is a continuous monolayer of l-6xl013 endothelial cells which form a tissue weighting 1.5-2.0 kg and having a total surface area of about 900 m2 in humans. The endothelium continuously produces an enormous number of crucial biologically active substances thus being a giant paracrine organ distributed across the entire area of the human body.
The main functions of endothelial cells include, inter alia, the following: regulation of vascular tone (vasoconstriction and vasodilation); regulation of hemostasis (thrombogenicity and atrombogenicity of the vascular wall); angiogenesis (formation of new blood vessels); participation in immune reactions (activation of leukocyte adhesion, production of cytokines) including an essential barrier immune function.
The endothelium is known to be able to produce biologically active substances (BAS) which maintain the tone of underlying vascular smooth muscle cells (SMC), preserve non-adhesiveness of intima, and influence inflammatory and immune mechanisms in the vascular wall. In addition to a barrier function, endothelial cells perform numerous functions in a tight relationship with SMCs. Therefore, the regulation of vascular tone is considerably associated with BAS synthesis by endothelial cells. Changes in physical, chemical and humoral parameters of the endothelial cell environment prompt them to produce a number of BAS: vasodilators - nitric oxide (NO), prostacyclin (PGI2), bradykinin, endothelium-derived hyperpolarizing factor (EDHF);
vasoconstrictors - endothelin-1, prostaglandin H2, superoxide anion, angiotensin II, thromboxane A2. Nitric oxide is the main factor controlling the vascular tone; it can regulate and distribute blood flow in various vascular pools by changing the diameter of both large and small arteries and arterioles via the stimulation of guanylate cyclase and an increase in the intracellular cGMP concentration. Subsequently, cGMP reduces the intracellular Ca2+ concentration resulting in vasodilation. In addition to the regulation of vascular tone, nitric oxide has many additional unique functions what makes it the main factor in antiatherogenesis. NO, as a universal signaling molecule, suppresses platelet adhesion to the endothelium and their aggregation, possesses anti-inflammatory properties, regulates the synthesis and breakdown of the extracellular matrix, prevents cell migration and proliferation, and controls gene transcription. Moreover, NO acts as a secondary messenger for many growth factors, peptides, blood coagulation factors and hormones, and also facilitates transendothelial migration of leukocytes and endothelial cell precursors. Along with this, the endothelium is involved in the regulation of blood coagulation (formation of fibrinolysis activators and inhibitors, pro- and antithrombotic factors) and vascular wall permeability (free radicals, protein kinase C).
It was also found that the endothelium is capable to regulate adhesive properties of the vascular wall (expression of adhesion molecules - ICAMs, YCAMs, as well as E- and P-selectins). P- and E-selectins are involved in leukocyte rolling, whereas ICAMs and VCAMs are responsible for their adhesion through the interaction with relevant ligands for white blood cells.
Since ED is associated with an imbalance between the production of vasodilators and vasoconstrictors, thrombogenic and atrombogenic factors, angiogenic substances and their inhibitors, it is subdivided into vasomotor, thrombophilic, adhesive and angiogenic forms. An increased adhesiveness of the endothelium and uncontrolled stopping of leukocytes underlie the adhesive ED form and play an important role in pathogenesis of inflammation in atherosclerosis and other pathological processes. The development of the thrombophilic ED form is mediated by an impaired ratio between factors which induce platelet adhesion and aggregation, thrombogenesis, suppress fibrinolysis (von Willebrand factor, platelet-activating factor, thromboxane A2, tissue factor, etc.), and atrombogenic substances (NO, prostacyclin, thrombomodulin, t-PA, etc.) with a predominance of the former ones. A significant decrease in vascular thromboresistance has been recorded in atherosclerosis, hypertension, diabetes mellitus, and tumor diseases. The loss of vascular endothelial cells accompanied by the exposure of basement membrane and accumulation of cell lysis products, fibrin, erythrocyte sludges, hemolysis products and other factors enhancing intravascular platelet aggregation lead to the development of chronic disseminated intravascular coagulation (DIC) and other diseases. The angiogenic ED form is associated with pathological angiogenesis - an excessive activity of VEGF-A and other growth factors, and impairment in the
system of angiogenesis regulators (angiopoietins, angiostatin, etc.). Finally, the vasomotor ED form is mediated by a defect in endothelial vasoactive substance performance and plays an important role in mechanisms of both a systemic increase in blood pressure and local angiospasm. A change in endothelium-dependent vascular relaxation occurs for many reasons: decreased NO production, enhanced inactivation of vasodilators, weakened diffusion of NO to the underlying smooth muscle cells, reduced availability of L-arginine deposits, a precursor of NO, increased degradation of NO by free oxygen radicals, and increased production of vasoconstrictors.
ED also includes accelerated desquamation of capillary endothelium, weakened intercellular junctions, impaired protein synthesis, as well as impaired expression and formation of adhesive glycoproteins on endothelial cells. This facilitates the attachment of monocytes and leukocytes, as well as their migration across the basement membrane.
Endothelial cells of either large or small vessels are insulin-independent cells. Therefore, under hyperglycemic conditions in diabetes mellitus glucose can freely enter into endothelial cells producing pathological biochemical reactions inside the cells which are an important cause of ED. Hyperglycemia delays the replication of endothelial cells and promotes cell death by increasing oxidative processes and glycation. ED is an integrated syndrome of insulin resistance, with exacerbation thereof, increases vascular reactivity, and provokes cardiovascular disorders.
ED is one of the earliest signs of vascular lesions in patients with DM and could be detected at the initial stages of the disease, even before the appearance of atherosclerotic plaques; endothelial dysfunction remains to be a concern at the later stages of atherosclerotic lesion because impairments of endothelium-dependent vascular relaxation and increased adhesiveness of the endothelial lining could provoke a constriction, and the formation and growth of a plaque followed by its rupture. Accordingly, ED also manifests as the impairment of vascular tone regulation and, as a consequence, central and peripheral hemodynamics. The second consequence is the impairment of substance transport through the vascular wall. Lipid accumulation in the vascular wall and their involvement in atherogenesis should be considered as one of the main manifestations of that.
Various antioxidants were amongst the first drugs used for treating endothelial dysfunction: vitamins C and E, N-acetylcysteine, genistein, and others. Vitamin C was shown to protect the endothelium against superoxide radical effects that prevents lipid oxidation, neutrophil adhesion and ultimately the development of endothelial dysfunction [Taddei S., Virdis A., Ghiadoni L, Magagna A., Salvetti A. Vitamin C improvesendo the lium-dependent vasodilation byrestoring nitricoxide activity in essential hypertension. Circulation. 1998; 97:2222-2229 ]. Vitamin E also has a protective effect on the endothelium in hypercholesterolemia but its use in diabetes mellitus produces an opposite effect [ Economides P.A, Khaodhiar L, Caselli A, Caballero A.E, Keenan H, Bursell S.E., King G.L., Johnstone M.T., Horton E.S., Veves A. The effect of vitamin E on
endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. Diabetes. 2005; 54:204-211\. N-acetyl cysteine influences the production of glutathione which is the main endogenous antioxidant protecting the endothelium against free radicals and the damaging effect of various cytokines, such as tumor necrosis factor alpha [ Bourraindeloup M., Adamy C, Candiani G., Cailleret M., Bourin M.C., Badoual T, Su J.B., Adubeiro S., Roudot-Thoraval F., Dubois-Rande J.L. N-acetylcysteine treatment normalizes serum tumor necrosis factor-alpha level and hinders the progression of cardiac injury in hypertensive rats. Circulation. 2004; 110:2003-2009] Moreover, N-acetylcysteine regulates the expression of metalloproteinases which cleave intercellular junction proteins of the endothelium that significantly contributes to the development of endothelial dysfunction [Moshal K.S., Sen U., Tyagi N., Henderson B., Steed M., Ovechkin A.V., Tyagi S.C. Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway. Am J Physiol Cell Physiol. 2006; 290:C883-C891] The main field of application of substances described above is chronic diseases accompanied by endothelial dysfunction.
Another group of drugs is related to prostacyclin, a substance from the class of prostaglandins. Prostaglandins are endogenous biologically active substances of lipid nature synthesized in almost all cells of the body. While prostaglandin E2 is involved in the development of inflammation, prostacyclin and some other prostaglandins have a vasodilatory effect, and also prevent platelet aggregation with endothelial cells. Prostacyclin and its synthetic analogs (iloprost, belaprost, ventavis, etc.) are successfully being used to reduce the permeability of endothelium in combined treatment of ischemia-reperfusion [H. Schutte, A.Lockinger, W.Seeger, et al. Aerosolized PGE1, PGI2 and nitroprusside protect against vascular leakage in lung ischaemia-reperfusion. Eur. Respir. J., 2001; 18:15-22] In endothelial cells, these substances are thought to induce the adenylate cyclase mechanism which reinforces the endothelial barrier by forming new or strengthening the already existing intercellular adhesion complexes. Therefore, prostacyclin was shown to reduce endothelial permeability in LPS-induced inflammation in mice by activating Rapl protein, one of the last participants in the adenylate cyclase pathway [Birukova A.A., Meng F.,Tian Y., Meliton A., Sarich N, Quilliam LA., Birukov K.G. Prostacyclinpost-treatmentimproves LPS- induce dacutelung in juryandendo the lialbarrier recovery via Rap 1. BiochimBiophysActa. 2015; 852 (5): 778-91] However, under certain conditions, an action of prostacyclin can be blocked by other cytokines leading to opposite effects, i.e., enhanced endothelial dysfunction [Blanco-Rivero J., Cachofeiro V., Lahera V., Aras-Lopez R, -Marquez-Rodas /., Salaices M., Xavier F.E., Ferrer M., Balfagon G. Participation of prostacyclininendo the lialdysfunction induced byaldosterone in normotensive and hypertensiverats. Hypertension 2005; 46:107-112]
Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor (AR) blockers are also antihypertensive agents and exert a protective action on the endothelium. Angiotensin II is a protein hormone synthesized from an inactive precursor angiotensin I by ACE. Angiotensin II has a strong vasoconstrictor effect and for this reason ACE is targeted by many drugs, such as perindopril, fosinopril, losartan, etc. The following positive effects of ACE inhibitors were observed amongst others: increased expression of NO-synthase in ischemia-reperfusion [B.Gemici, R.Tan, G.Ongut, V.N. Izgut-Uysal Expressions of induciblenitricoxidesynthase and cyclooxygenase- 2 ingastricis chemia - reperfusion: role of angiotensinll. J SurgRes, 2010; 161:126-133 ], decreased apoptosis of endothelial cells, decreased concentrations of tumor necrosis factor alpha and other pro-inflammatory cytokines \A.M. Kampoli, D.Tousoulis, C.Tentolouris, C.Stefanadis Novelagentstargetingnitricoxide. CnrrVascPharmacol, 2012; 10:61-76]. ACE inhibitors and angiotensin receptor blockers were also shown to have a beneficial effect on the endothelium in coronary heart disease and hypercholesterolemia [ B.Hornig , U.Landmesser, C.Kohler, D.Ahlersmann, S.Spiekermann, A.Christoph, Comparative effect of aceinhibition and angiotensin II type 1 recept or antagonism on bioavailability of nitricoxidein patients with coronaryarterydisease: role of super oxidedismutase. Circulation, 2001; 103:799-805 ].
Different drugs for the treatment of diseases related to endothelial dysfunction are also widely known from patent literature (see, for example, RU 2464019, RU 2657416, RU 2505290).
Therefore, in veterinary and medicine there is still a need for the development of alternative, preferably more effective, means and methods for preventing or treating ED and/or ED-related diseases and conditions, as well as means which could find application in conjunction with conventional means for preventing or treating ED and/or ED-related diseases and conditions.
An object of the present invention was to provide a more effective method for the prevention and treatment of ED and/or ED-related conditions.
SUMMARY OF THE INVENTION
The present invention is a result of continuing the development and investigation of properties of the composition described in patent RU 2526826, issued in the name of present inventor. In particular, patent RU 2526826 discloses the composition for parenteral administration comprising a hydrolysate based on biological raw materials obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches, and water, and having a broad spectrum of action and properties. Surprisingly, additional studies aimed at assessing the efficacy of treatment of ED induced in laboratory conditions in mice, as well as an increase in the levels of nitric oxide (NO) release in human endothelial cells in vitro, described below in this specification, have demonstrated that said composition is an effective means
for treating or preventing ED, as well as an ED-related disease or condition. The disclosure of patent RU 2526826 is entirely incorporated herein by reference.
Therefore, the present disclosure provides a use of a composition based on a hydrolysate obtained from one or more biological resources selected from the group including bivalve mollusks, annelids, and leeches, for the prevention or treatment of ED, as well as diseases or conditions accompanied by or related to ED, in a mammal in need of such prevention or treatment.
Said composition comprises a wide range of essential amino acids, melanoidins acting as antioxidants, regulatory peptides, saturated and unsaturated fatty acids, macro- and microelements in a balanced native natural ratio, and, inter alia, has an immunomodulating property and is employed for therapeutic and/or prophylactic purposes in veterinary and medicine.
More specifically, in a first aspect, the present invention provides a use of a composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of endothelial dysfunction in a mammal in need of such treatment or prevention.
In a second aspect, the present invention provides a use of a composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of endothelial dysfunction and/or a disease or condition related to endothelial dysfunction in a mammal in need of such treatment or prevention.
In a third aspect, the present invention provides a use of a composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of a disease or condition with concomitant endothelial dysfunction in a mammal in need of such treatment or prevention.
In yet another aspect, the present invention relates to the composition for use according to any of applications described above.
In a fourth aspect, the present invention provides a method for the treatment or prevention of endothelial dysfunction in a mammal in need of such treatment or prevention, comprising parenteral administration of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, to said mammal.
In a fifth aspect, the present invention provides a method for the treatment of endothelial dysfunction and/or a disease or condition related to endothelial dysfunction in a mammal in need of such treatment or prevention, comprising parenteral administration of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, to said mammal.
In a sixth aspect, the present invention provides a method for the treatment of a disease or condition with concomitant endothelial dysfunction in a mammal in need of such treatment or prevention, comprising parenteral administration of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, to said mammal.
Various embodiments of the present invention are described below in the “Detailed Description” section. Each of said specific embodiments of the invention is to be understood as relating to any of aspects of the invention specified above.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows study data demonstrating the effect of enhancing eNOS activity in human umbilical cord vein endothelial cells (HUVECs) by using the composition according to the present invention.
Fig. 2 shows study data demonstrating the effect of reducing the expression of adhesion molecules VCAM and ICAM in human umbilical cord vein endothelial cells (HUVECs) by using the composition according to the present invention.
Fig. 3 shows study data demonstrating the effect of reducing iNOS activity in the cell culture from peritoneal lavage of mice.
DETAILED DESCRIPTION
A disturbance of endothelium functions is one of universal mechanisms of pathogenesis of many diseases including common ones such as atherosclerosis, hypertension, and diabetes mellitus. Dysfunction of the endothelium or endothelial dysfunction (ED) plays a role in the development of thrombosis, neoangiogenesis, vascular remodeling, and intravascular activation of platelets and leukocytes. The predominant impairment of one or another function of the endothelium depends on the localization of pathological processes, prevalence of one or other of inflammatory mediators, and presence of hemodynamic shifts. An implication of the endothelium in the regulation of vasomotor reactions, hemostasis, angiogenesis, vascular-tissue migration of leukocytes was the most comprehensively studied. The impairment of these particular processes is a nonspecific chain in pathogenesis of many diseases.
Endothelial dysfunction is one of the most important pathogenetic mechanisms of many cardiovascular diseases. In particular, endothelial dysfunction could cause vasoconstriction, increased clotting and enhanced adhesion of leukocytes to the endothelium which is accompanied by the impairment of regional blood circulation and microcirculation.
Endothelial dysfunction can be caused by the following factors: genetic features; age-related changes; dyslipoproteinemia (hypercholesterolemia); hypercytokinemia; hyperhomocysteinemia; hyperglycemia; hemodynamic factor (hypertension, ischemia, venous stasis); endogenous intoxications (renal failure, hepatic failure, pancreatitis, etc ); exogenous intoxications (smoking, etc.)
Recent years have led to the understanding that endothelial dysfunction represents a state of the endothelium with insufficient production of nitric oxide (NO). Since nitric oxide is involved in the regulation of almost all functions of the endothelium (regulation of vascular tone, vascular thromboresistance, regulation of leukocyte adhesion and vascular permeability), and additionally is the factor most sensitive to a lesion, this insight into endothelial dysfunction is quite correct, although not entirely comprehensive. The most important factor interfering nitric oxide formation and/or bioavailability is an excessive generation of reactive oxygen species observed in many diseases.
One of the methods for evaluating the severity of ED is the assessment of various substances, which are produced in the endothelium, in the blood. At present, there are techniques for determining in the blood almost all known substances produced in the endothelium; however, not all indicators have the same diagnostic value, since a significant portion of ED markers is produced not only in the endothelium but in other cells as well. By the degree of specificity, the most considerable are, in particular, nitric oxide, prostacyclin, endothelin-1, ICAM-1, VCAM-1, E- selectin, annexin-II, thrombomodulin and others. Some of indicated factors, for example, nitric oxide and prostacyclin, are constantly synthesized in the endothelium, and the disturbance of their synthesis or decrease in bioavailability may indicate the presence of lesions in the endothelium. At the same time, inducible nitric oxide synthase and cyclooxygenase-2 are generated in the endothelium that leads to a significant elevation in the production of NO and prostacyclin. In normal conditions, factors such as endothelin-1, ICAM-1, VCAM-1, and E-selectin are virtually not synthesized; however, their concentrations sharply rise upon activation of the endothelium. Factors
such as intracellular proteins (tissue factor, annexin-V) or endothelial membrane receptors (thrombomodulin, protein C receptor) are observed in the blood upon damage of the endothelium or apoptosis.
Since nitric oxide (NO) is involved in very different bioregulatory effects of the vascular process, a decline in its level in endothelial cells (ECs), due to various factors, leads to significant changes in their functions and the circulatory system in general. Impairments are manifested (Shiffrin E.L., 2001; Egashira K., 2002; Feletou M., 2006; Cooke J.P., 2003, Endemann D.H., 2004, Zolotova I.V. (3oToea H.B.), 2000; Markov K.M. (MapxoB X.M.), 2005) by: decreased efficacy of endothelium-dependent vasodilators and, as a consequence, enhanced vasoconstrictive effects, increased blood pressure, impaired local, regional and systemic hemodynamics, disturbance of cardiac activity, elevated production of adhesive substances in the endothelium which leads to the aggregation of platelets, and adhesion of them and leukocytes to the vascular wall, proliferation and/or migration of smooth muscle cells with the formation of neointima, synthesis of the extracellular matrix, etc.
Studies in recent years have convincingly demonstrated that the specified impairments constituting endothelial dysfunction as a whole occur in various combinations during many cardiovascular diseases (hypertension, atherosclerosis, CAD, heart failure, circulatory disorders in kidneys, lungs, brain, limbs, intestines (Belousov Yu.B. (Benoycoe BD.E.), 2000; Makolkin V.I. (MCIKOJIKUH B.H.), 2004; Borovkov N.N. (Eorobkob H.H.), 2005; Cooke J.P., 2003; Landmesser U., 2004), as well as in the presence of risk factors of these diseases (hypercholesterolemia, tobacco smoking, diabetes mellitus, insulin resistance, obesity, hypokinesia, aging of the body, hereditary burden) (Shestakova M.V. ( UlecmaKoea M.B. ), 2001; Buvaltsev V.I. (Eyeaibi/ee B.H.), 2002; Petrishchev N.N. (IJempmi ee H.H.), 2003; Vertkin A. A. (Be pm k an A.A.), 2005; Mazurov V.I. ( Ma3ypoe B.M.), 2006; Bonetti P.O., 2003; Barbato J.E., 2004; Spieker L.E., 2006; Giannotti G., 2007).
Nitric oxide is synthesized in the endothelium (by isoforms of the enzyme NO-synthase: 2 of them are constitutive - endothelial (eNOS) and neuronal and 1 is inducible (iNOS)) through the reaction of amino acid L-arginine, with the involvement of molecular oxygen. A catalyst is the enzyme NO-synthase. The reaction can be schematically depicted as follows: L-arginine + 02®L- citrulline + NO. Constitutive endothelial NO-synthase (eNOS) is involved in the cardiovascular system regulation. Nitric oxide is synthesized stepwise with the formation of intermediate N- hydroxy-L-arginine.
Once formed, nitric oxide is released from endothelial cells and diffuses into the deeper myocytes of the vascular walls. By acting on vascular myocytes nitric oxide (NO) activates guanylate cyclase that leads to an increase in the content of 3,5-cyclic guanosine monophosphate, these processes provoke a decrease in the calcium concentration resulting in relaxation of smooth muscle cells and vasodilation [Cavelin, caveolae and endothelium cell function. / Frank P.O., Woodman S.E., Park D.S., Lisanii M.P. // ArteriosclerThrombVaseBiol 2003; 23:1161-1168., Zotova, I.V. (3oTOBa, H.B.) Synthesis of nitric oxide and the development of atherosclerosis / I.V. Zotova (3oTOBa, H.B.), D.A. Zateyshchikov (/f AGaTeiimuKOB), B.A. Sidorenko (B.A.CunopeHKo) // Cardiology. - 2000. - No. 4. - C.58-67, Luscher T.F., Endothelial control of vascular tone and growth // Clin. Exp.Hypertens - JV° 12. - 1990 - P.897-902, Luscher T.F., Endothelium - derived vasoactive factors and regulation of vascular tone in human blood vessels // Lung. - V.168. - 1990. - P.27-34]
Slowing down the expression and activity of endothelial NO-synthase (eNOS) is typically associated with endothelial dysfunction. Endogenous eNOS inhibitors are the first in a series of factors leading to this, for example, ADMA [Association analysis of CA repeat polymorphism of the endothelial nitric synthase gene to essential hypertension in Japanese. NakaymaT., Soma J., Takahashi J. el al. Clin Genet 1997; 51:26-30., Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Circulation 99: 1141-1146, 1999, Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Boger R.H., Bode-Boger S.M., SzubaA. et al. Circulation 1998; 98:1842-1847., Cooke J.P. Does ADMA cause endothelial dysfunction. Arterio-sclerThromb Vase Biol 2002; 20:2032-2045]
By conducting a series of studies, the present inventors have found that the composition obtained on the basis of hydrolysate from biological resources and previously described in patent RU 2526826 may be used to increase eNOS activity and reduce iNOS activity in the body of a mammal in need of prevention or treatment of endothelial dysfunction and/or an ED-related condition or disease, as well as to increase nitric oxide concentrations, decrease adhesion molecules VCAM-1 and ICAM-1 in endothelial cells of said mammal, suggesting that said composition may be effectively employed for treating a number of pathological conditions and diseases related to ED.
In a first aspect, the present invention provides a use of a composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of ED and/or an ED-related disease or condition in a mammal in need of such treatment or prevention.
Said hydrolysate is a product of hydrolysis of biological raw materials. In one embodiment, biological resources are selected from the group including bivalve mollusks, crustaceans, annelids, and leeches. Said biological resources allow for obtaining the hydrolysate with a balanced chemical composition comprising, inter alia, a wide range of amino acids including essential amino acids, saturated and unsaturated fatty acids, melanoidins, carbohydrates, micro- and macroelements, which serves as the basis for manufacturing the composition allowing to achieve the desired therapeutic and prophylactic effect when administered parenterally to a mammal in need of such treatment or prevention.
Preferably, said biological raw materials are bivalve mollusks including swan mussel ( Anodonta ), pearl shell ( Unio ), oysters ( Ostreidae ), mytilids ( Mytilidae ), tridacna ( Tridacna ), pearl oysters ( Pinctada ), scallops (. Pectinidae ), shipworms ( Teredinidae ), goeduck (Panopea abrnpta ), Icelandic cyprine (Arctica Islandica) and other commercial types of mollusks.
By the term “hydrolysate obtained from biological resources” in the context of this specification is understood a liquid solution obtained by enzymatic and/or acidic hydrolysis of the biological resources described above. Various methods for conducting hydrolysis of biological resources are known in the art and can be selected by a person skilled in the art when implementing the present invention. In particular, patents RU 2134523, RU 2374892, RU 5042669, RU 2090084, RU 2066105, RU 2134523, RU 2319409 describe various conditions for conducting the hydrolysis of protein raw materials suitable according to the present invention.
In one embodiment, commercially available hydrolysates from mytilids including but not limiting to MIDEL («MH¾3JI»), MIGI-K («MHGΉ-K»), may be used as an initial hydrolysate for producing the composition.
The dilution factor of solution obtained immediately after aqueous hydrolysis is determined empirically by a person skilled in the art such that the amount of mineral salts, in particular sodium chloride, in the final product (composition) does not exceed the total blood salinity of a mammal to which the composition is to be administered. In one embodiment of the present invention, the amount of hydrolysate in the composition is 2 to 8 wt.%, preferably 3 to 7 wt.%, more preferably 4 to 6%, most preferably about 5 wt.%. In another embodiment, the amount of hydrolysate may be 1 to 4 wt.%, 1 to 3 wt.%, 1 to 2 wt.%, 6 to 9 wt.%, 7 to 9 wt.% and 8 to 9 wt.%. The remaining portion is water and optionally auxiliary ingredients, e.g. glucose.
The amount of hydrolysate does not typically exceed 10 wt.% of the composition, as otherwise the composition will not be suitable for certain types of parenteral administration, in particular, injectional administration, due to the presence of high salt concentration therein. However, the weight fraction of hydrolysate is typically at least 1 wt.% to provide the composition
with sufficient amount of components for achieving a desired effect in treating and/or preventing ED and ED-related diseases and conditions.
At the same time, the final dilution factor of hydrolysate, as will be appreciated by a person skilled in the art, will be defined by specific conditions for conducting the hydrolysis of initial biological raw materials and the need for dilution in general, depending on the method of administration of the composition, a species of mammal and other conditions.
In another embodiment, said composition is characterized by the weight fraction of amine nitrogen of at least 0.01 wt.%. Preferably, the weight fraction of amine nitrogen is 0.01 to 0.5 wt.%. More preferably, the weight fraction of amine nitrogen is 0.05 to 0.5 wt%, most preferably 0.02 to 0.1 wt.%. The value of weight fraction of amine nitrogen characterizes the conversion rate for hydrolysis of biological resources and represents a factor which allows for assessing the completeness of this process. This characteristic serves as an indirect indicator of the presence of necessary components within the final composition for parenteral administration when using biological resources in accordance with this specification.
In another embodiment, the provided composition has pH value 4 to 7, preferably 5 to 7, most preferably 5.5 to 6.5. The pH value within the above range indicates a sufficient degree of hydrolysate neutralization, as well as the possibility of using said composition for therapeutic and/or prophylactic purposes in mammals.
In another embodiment, the provided composition has the weight fraction of solids 0.5 to 5 wt.%, preferably 1 to 3 wt.%, most preferably 1.2 to 1.8 wt.%.
By the term “disease or condition related to endothelial dysfunction” is understood the condition and disease which development or pathogenesis is related to the impairment of normal functioning of endothelial cell layer or its damage. In other words, the course of said conditions or diseases is accompanied by the impairment of normal functioning of endothelial cell layer or its damage, or by diagnosed endothelial dysfunction.
In particular, by the disease or condition in the context of this specification is understood one of diseases or conditions selected from the group including: atherosclerosis, hypertension, coronary failure, myocardial infarction, insulin resistance, diabetes mellitus, renal failure, hereditary and acquired metabolic disorders (dyslipidemia, etc.),
endocrine age-related disorders, respiratory pulmonary pathologies (asthma), abdominal adhesions, major surgeries, hypothermia, bums (thermal and chemical), extensive blood loss, heart attack, stroke, sepsis, septic shock, cancers, tick-borne diseases, multiple organ failure, vascular dementia,
Alzheimer's disease,
Parkinson's disease, autoimmune diseases, senility, asthma, acute lung injury, acute respiratory distress syndrome,
Middle East respiratory syndrome, chronic obstructive pulmonary disease, viral infections, including infections caused by coronaviruses, including SARS-CoV, SARS- CoV-2, preeclampsy, eclampsy, pregnancy-induced hypertension with significant proteinuria, emphysema, asthma, asthmatic condition, bronchiectasis peripheral vascular diseases, arterial embolism and thrombosis,
capillary diseases,
ED of geriatric etiology, chronic renal failure, nephrotic syndrome chronic tubulointerstitial nephritis, glomerulonephritis.
Furthermore, an ED-related condition may be any disease specified in the International Classification of Diseases (ICD 10) in sections C22 (Malignant neoplasm of liver and intrahepatic bile ducts), C26 (Malignant neoplasm of other and ill-defined digestive organs) and T22 (Thermal and chemical body burns), as well as other diseases disclosed in this specification.
It is to be understood that the present invention alternatively provides the use of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of any disease or condition from the group above with concomitant endothelial dysfunction, in a mammal in need of such treatment or prevention.
Furthermore, the present invention provides the use of the composition disclosed in this specification for the prevention or treatment of endothelial dysfunction. This embodiment includes the treatment of endothelial dysfunction, regardless of the presence or absence of any concomitant diseases or conditions specified above.
In one embodiment, the composition is administered “parenterally” which means any methods of administration, excluding entry of the provided composition into the body of a mammal in need thereof through the gastrointestinal tract. In particular, parenteral administration may be injectional, intranasal, subconjunctival administration of the composition in the form of solutions, the use of solutions in the form of gargles, rinsing, soaking treatments, wraps, as well as applying the composition onto affected surface in the form of creams, ointments, gels on a hydrophilic base.
In one specific embodiment, the composition is additionally sterilized and represents the composition for injectional administration. Said injectional administration can be carried out intravenously (i.v.), intradermally, subcutaneously (s.c.), intramuscularly (i.m.) or intraosseously (i.o.), wherein said administration can be carried out in a continuous (permanent) mode using a dropper, various drug dispensers, including osmotic pumps, pumps (similar to insulin pumps), or another suitable dispensing device.
By the term “mammal in need of such treatment or prevention” is understood any animal from the class of “mammals”, including humans, in need of treatment or prevention of ED and/or ED- related conditions and diseases.
In one embodiment, the mammal may be an animal or a human. For example, the animal may be a farm animal selected from the group including a cow, buffalo, yak, deer, pig, goat, sheep, rabbit, horse, donkey, camel, lama, sable, fox, mink, ferret, etc., or the animal may be a domestic pet, e.g., such as dog, cat, rat, hamster, guinea pig, etc., or the animal may be a wild animal. In a specific embodiment, the animal is a mouse.
In one embodiment, the composition is administered to said mammal for 1-5 days at a dosage of 0.2 to 6.0 pil · k g/h In particular, this administration may be carried out by continuous parenteral administration, in particular subcutaneous, intravenous or intramuscular injection using a suitable dosing device, for example, dropper, pump (similar to insulin pump), osmotic pump. This dosage was found to be effective in treating/eliminating ED and ED-related diseases and diseases. In this respect, a skilled person in medicine or veterinary will be able to select empirically a necessary specific dosage taking into account characteristics of patient's body, disease severity and other conditions.
In another embodiment, the composition is administered to said mammal at a dosage of 10- 400 pl/h for 1-5 days. In particular, the administration may optionally be carried out by continuous parenteral administration, in particular subcutaneous, intravenous or intramuscular injection using a suitable dosing device, for example, dropper, pump, or osmotic pump.
According to one of the most preferred embodiments, the composition is administered continuously (permanently) into the body of a mammal in need thereof using an osmotic pump, pump or dropper.
In an additional embodiment, the composition is administered to said mammal for 7-10 days.
In one embodiment, the use of said composition may include concurrent administration of said composition and means of conventional combination therapy for the prevention or treatment/elimination of ED in a patient in need thereof.
In a second aspect, the present invention provides a method for the treatment/elimination of ED and/or ED-related diseases and conditions in a mammal in need of such treatment or prevention, comprising parenteral administration of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, to said mammal.
It is to be understood that the present invention alternatively provides a method for the prevention or treatment of the disease or condition from the group of conditions or diseases disclosed in this specification with concomitant endothelial dysfunction, in a mammal in need of such treatment or prevention, using the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water.
Furthermore, the present invention provides a method for treating endothelial dysfunction using the composition disclosed in this specification. This embodiment includes the treatment of endothelial dysfunction, regardless of the presence or absence of any of concomitant diseases or conditions related to endothelial dysfunction.
In one embodiment, the composition is administered to said mammal for 1-5 days at a dosage of 0.2 to 6.0 pl*kg/h. In particular, this administration may be carried out by continuous parenteral administration, in particular subcutaneous, intravenous or intramuscular injection using a suitable dosing device, e.g., dropper, pump or osmotic pump.
In yet another embodiment, the composition is administered to said mammal at a dosage of 10-400 mΐ/h for 1-5 days In particular, said administration may optionally be carried out by continuous parenteral administration, in particular subcutaneous, intravenous or intramuscular injection using a suitable dosing device, e.g., dropper, pump or osmotic pump.
In an additional embodiment, the provided method of treatment comprises the use of the composition intended for injectional administration which is administered to said mammal for 7-10 days.
In still further embodiment, the provided method of treatment comprises the use of the composition intended for injectional administration and may further comprise the repeated course which is carried out in 1-2 days upon completion of the first one.
In one embodiment, the provided method of treatment comprises the use of the composition intended for injectional administration, and may comprise the concurrent use of said composition and means of conventional combination therapy for the prevention or treatment of ED and/or ED- related diseases and conditions in a patient in need thereof.
Efficiency of using the composition for the treatment and prevention of ED, as well as ED- related diseases and conditions is discussed in more detail below by specific examples of its implementation.
EXAMPLES
EXAMINING THE ACTIVITY OF COMPOSITION IN RELATION TO FACTORS OF ENDOTHELIAL DYSFUNCTION
EXAMPLE 1: Effect of the composition on eNOS activity
For the analysis of eNOS activity human umbilical cord vein endothelial cells (HUVECs) were added to 12-well plates (Sarstedt) and cultured until a confluent monolayer formed. The composition containing 5% wt. hydrolysate from mytilids and water was then added at various dilutions and incubated for 72 h at 37°C in humidified atmosphere with 5% CO2. At the end of
incubation period, the DAF-FM DA dye (Invitrogen) was added at a concentration of 1 mM and incubated for 1 h. The monolayer was disintegrated and cells were fixed with 4% formaldehyde solution (Sigma). Sample measurements were conducted using Navios™ flow cytometer (Beckman Coulter).
The study results are shown in Fig. 1. In particular, the composition based on the hydrolysate from mytilids was shown to activate eNOS and increase the production of NO by almost 3 times.
EXAMPLE 2: Effect of the composition on expression of VCAM-1 and ICAM-1
To assess the expression of surface molecules VCAM-1 (CD 106) and ICAM-1 (CD54), HUVECs were added to 24-well plates (Sarstedt) at a concentration of 150,000 cells per ml. The composition containing 5% wt. hydrolysate from mytilids and water was then added for 72 hours at different dilutions. TNFa was added to wells at a concentration of 25 U/ml 24 hours before the end of incubation. The expression of surface molecules was assessed by flow cytometry using anti- CD106PE (cat. #PN A66085) and anti-CD54PE (cat. #PN IM1239U) monoclonal antibodies. Cell suspensions were stained according to manufacturer's recommendation. To assess necrosis level cell suspension was additionally stained with the DNA-binding dye DAPI (Invitrogen) at a concentration of 1 mg/ml. Samples were analyzed using Navios™ flow cytometer (Beckman Coulter).
The study results are shown in Fig. 2. The obtained results indicate that the composition based on the hydrolysate from mytilids reduces the expression of VCAM-1 on HUVECs after induction with TNF-alphaby 3.6 times.
EXAMPLE 3: Effect of the composition on iNOS activity.
To analyze the effect of the preparation on iNOS activity, mouse peritoneal lavage cell culture was used. CBA/BALB (FI) mice from the “Rappolovo” nursery were kept under conditions of unlimited access to food and water in accordance with accepted ethical standards. Peritoneal lavage cells were obtained by washing the abdominal cavity of mice with sterile Hanks solution. Cells were added to 96-well plate (Eppendorf, RF) in the amount of 300,000 in 100 pi of RPMI 1640 medium (Biolot, RF) with 10% fetal calf serum (Flow laboratories, USA) supplemented with 2 mM glutamine (Biolot, RF), 50 pg/ml gentamicin (Biolot, RF), and incubated for 24 hours at temperature of 37°C, 5% CO2.
After the culture medium was replaced to stimulate NO production, LPS (Esherichia coli 055 :B5, Sigma-Aldrich, Germany) at a concentration of 1 pg/ml and the composition containing 5% wt. hydrolysate from mytilids and water were added to wells. After incubation for 24 hours at 37°C and 5% CO2 cells were sedimented by centrifugation for 5 min at 200g. Then 70 mΐ of
supernatant was collected, transferred to 96-well plate (Eppendorf, RF), and 70 mΐ of Griss reagent was added. Spectrometric analysis was conducted at a wavelength of 540 nm (Microplate reader, Model 680, Bio-Rad). Nitrite and nitrate concentrations in experimental samples were determined mathematically in accordance with linear fitting by the method of least squares based on the calibration curve constructed using sodium nitrite (NaNCh) solution with known concentration.
Data analysis and processing were performed using STATISTICA 5.0 software using Student's t-test.
The study results are shown in Fig. 3. Incubation of cells with the preparation led to a significant decrease in the level of spontaneous ICAM-1 expression. The preparation based on the composition with dilution of 1:3 (v/v) significantly decreased spontaneous and LPS-induced levels of ICAM-1 expression.
Claims
1. A composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for use in the prevention or treatment of endothelial dysfunction and/or a disease or condition related to endothelial dysfunction in a mammal in need of such treatment or prevention.
2. The composition according to claim 1, wherein the composition comprises 1 to 10% of the hydrolysate, and the remaining portion is water.
3. The composition according to claim 1, wherein the composition is administered parenterally, wherein said administration may be injectional, intranasal, subconjunctival administration of the composition in the form of solutions, the use of solutions in the form of gargles, rinsing, soaking treatments, wraps, as well as applying the composition onto affected surface in the form of creams, ointments, gels on a hydrophilic base.
4. The composition according to claim 1, wherein the injectional administration may be carried out intravenously (i.v.), intradermally, subcutaneously (s.c.), intramuscularly (i.m.) or intraosseously.
5. The composition according to claim 1, wherein the disease or condition is selected from the group including:
- atherosclerosis,
- hypertension, - coronary failure,
- myocardial infarction,
- insulin resistance,
- diabetes mellitus,
- renal failure,
hereditary and acquired metabolic disorders (dyslipidemia, etc.), endocrine age-related disorders, respiratory pulmonary pathologies (asthma), abdominal adhesions, major surgeries, hypothermia, bums (thermal and chemical), extensive blood loss, heart attack, stroke, sepsis, septic shock, cancers, tick-borne diseases, multiple organ failure, vascular dementia,
Alzheimer's disease,
Parkinson's disease, autoimmune diseases, senility, asthma, acute lung injury, acute respiratory distress syndrome,
Middle East respiratory syndrome, chronic obstructive pulmonary disease,
- viral infections, including infections caused by coronaviruses, including SARS- CoV, SARS-CoV-2,
- preeclampsy,
- eclampsy,
- pregnancy-induced hypertension with significant proteinuria,
- emphysema,
- asthma,
- asthmatic condition,
- bronchiectasis
- peripheral vascular diseases,
- arterial embolism and thrombosis,
- capillary diseases,
- ED of geriatric etiology,
- chronic renal failure,
- nephrotic syndrome,
- chronic tubulointerstitial nephritis,
- glomerulonephritis.
6. The composition according to claim 1, wherein the composition is administered to the mammal at a dosage of 0.2 to 6.0 pbkg/h for 1-5 days.
7. The composition according to claim 1, wherein the composition is administered to the mammal at a dosage of 10-400 mΐ/h for 1-5 days.
8. The composition according to claim 1, wherein the composition is administered using an osmotic pump, dropper or pump.
9. The composition according to claim 1, wherein the composition is administered to the mammal for 7-10 days.
10. A method for the treatment of endothelial dysfunction and/or a disease or condition related to endothelial dysfunction in a mammal in need of such treatment or prevention, comprising parenteral administration of the composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, to said mammal.
11. The method according to claim 10, wherein the disease or condition is selected from the group including: atherosclerosis, hypertension, coronary failure, myocardial infarction, insulin resistance, diabetes mellitus, renal failure, hereditary and acquired metabolic disorders (dyslipidemia, etc.), endocrine age-related disorders, respiratory pulmonary pathologies (asthma), abdominal adhesions, major surgeries, hypothermia, bums (thermal and chemical), extensive blood loss, heart attack, stroke,
sepsis,
- septic shock,
- cancers, tick-borne diseases,
- multiple organ failure,
- vascular dementia,
- Alzheimer's disease,
- Parkinson's disease, autoimmune diseases,
- senility,
- asthma,
- acute lung injury, acute respiratory distress syndrome,
- Middle East respiratory syndrome,
- chronic obstructive pulmonary disease,
- viral infections, including infections caused by coronaviruses, including SARS- CoV, SARS-CoV-2,
- preeclampsy,
- eclampsy,
- pregnancy-induced hypertension with significant proteinuria,
- emphysema,
- asthma,
- asthmatic condition,
- bronchiectasis
- peripheral vascular diseases,
- arterial embolism and thrombosis,
- capillary diseases,
- ED of geriatric etiology,
- chronic renal failure, nephrotic syndrome, - chronic tubulointerstitial nephritis,
- glomerulonephritis.
12. The method according to claim 10, wherein the composition is administered to the mammal at a dosage of 0.2 to 6.0 pl*kg/h for 1-5 days.
13. The method according to claim 10, wherein the composition is administered to the mammal at a dosage of 10-400 mΐ/h for 1-5 days.
14. The method according to claim 10, wherein the composition is administered using an osmotic pump, dropper or pump.
15. The method according to claim 10, additionally comprising the combined use of the composition and means of conventional combination therapy for the prevention and/or treatment of endothelial dysfunction or the disease or condition related to endothelial dysfunction in said mammal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2020113230A RU2020113230A (en) | 2020-04-09 | 2020-04-09 | APPLICATION OF COMPOSITION BASED ON BIORESOURCES FOR PREVENTION OR TREATMENT OF ENDOTHELIAL DYSFUNCTION, METHODS FOR PREVENTION OR TREATMENT OF ENDOTHELIAL DYSFUNCTION |
| RU2020113230 | 2020-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021206589A1 true WO2021206589A1 (en) | 2021-10-14 |
Family
ID=78023453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU2021/050094 WO2021206589A1 (en) | 2020-04-09 | 2021-04-09 | Composition for the prevention or treatment of endothelial dysfunction |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2020113230A (en) |
| WO (1) | WO2021206589A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2302241C1 (en) * | 2005-12-28 | 2007-07-10 | Михаил Владимирович Покровский | Method for correcting endothelial dysfunction with combination of indapamide and resveratrol at l-name-induced deficiency of nitrogen oxide |
| RU2526826C2 (en) * | 2012-10-24 | 2014-08-27 | Николай Владимирович Соловьёв | Parenteral composition, method for preparing and using composition |
| RU2622745C2 (en) * | 2015-08-31 | 2017-06-19 | Энту Фармасьютикалс Лтд | Based on bioresources compositions for prevention or treatment of sepsis and/or sepsis-related complications and conditions, methods for sepsis prevention and treatment |
-
2020
- 2020-04-09 RU RU2020113230A patent/RU2020113230A/en unknown
-
2021
- 2021-04-09 WO PCT/RU2021/050094 patent/WO2021206589A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2302241C1 (en) * | 2005-12-28 | 2007-07-10 | Михаил Владимирович Покровский | Method for correcting endothelial dysfunction with combination of indapamide and resveratrol at l-name-induced deficiency of nitrogen oxide |
| RU2526826C2 (en) * | 2012-10-24 | 2014-08-27 | Николай Владимирович Соловьёв | Parenteral composition, method for preparing and using composition |
| RU2622745C2 (en) * | 2015-08-31 | 2017-06-19 | Энту Фармасьютикалс Лтд | Based on bioresources compositions for prevention or treatment of sepsis and/or sepsis-related complications and conditions, methods for sepsis prevention and treatment |
Non-Patent Citations (1)
| Title |
|---|
| OH YUNOK, CHANG-BUM AHN, KI-HO NAM, YEON-KYE KIM, NA YOUNG YOON, JAE-YOUNG JE: "Amino Acid Composition, Antioxidant, and Cytoprotective Effect of Blue Mussel (Mytilus edulis) Hydrolysate through the Inhibition of Caspase-3 Activation in Oxidative Stress-Mediated Endothelial Cell Injury", MAR DRUGS, vol. 17, no. 2, 1 February 2019 (2019-02-01), pages 135, XP055865086, DOI: 10.3390/md17020l35 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020113230A3 (en) | 2021-10-11 |
| RU2020113230A (en) | 2021-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Prauchner | Oxidative stress in sepsis: Pathophysiological implications justifying antioxidant co-therapy | |
| Quiles et al. | The role of mitochondrial fission in cardiovascular health and disease | |
| Jalan et al. | Acute-on-chronic liver failure: pathophysiological basis of therapeutic options | |
| Malinski | Nitric oxide and nitroxidative stress in Alzheimer's disease | |
| Algaidi et al. | Long-term homocysteine exposure induces alterations in spatial learning, hippocampal signalling and synaptic plasticity | |
| JP2019069942A (en) | Peptide therapeutics and methods for using the same | |
| Parfenova et al. | Cerebroprotective functions of HO-2 | |
| Wang et al. | ROCK1 regulates sepsis-induced acute kidney injury via TLR2-mediated endoplasmic reticulum stress/pyroptosis axis | |
| Owada et al. | Resolution of mitochondrial oxidant stress improves aged-cardiovascular performance | |
| Dias et al. | Hemodynamic responses to Lachesis muta (South American bushmaster) snake venom in anesthetized rats | |
| Matsumoto et al. | Mechanisms underlying enhanced contractile response to endothelin-1 in diabetic rat basilar artery | |
| Shi et al. | The histone deacetylase inhibitor SAHA exerts a protective effect against myocardial ischemia/reperfusion injury by inhibiting sodium-calcium exchanger | |
| WO2021206589A1 (en) | Composition for the prevention or treatment of endothelial dysfunction | |
| Xia et al. | Lithium protection of phencyclidine-induced neurotoxicity in developing brain: the role of phosphatidylinositol-3 kinase/Akt and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling pathways | |
| Meschin et al. | p11 modulates calcium handling through 5-HT4R pathway in rat ventricular cardiomyocytes | |
| Schaefer et al. | Single donor infusion of S-nitroso-human-serum-albumin attenuates cardiac isograft fibrosis and preserves myocardial micro-RNA-126-3p in a murine heterotopic heart transplant model | |
| US8883744B2 (en) | Method and composition for modulating canonical Wnt pathway using folate and inositol | |
| NZ586518A (en) | Use of meldonium salts to treat myocardial infarction | |
| Zhang et al. | Bombesin protects myocardium against ischemia/reperfusion injury via activation of the Keap1-Nrf2-HO-1 signaling pathway | |
| US9308210B2 (en) | Method for modulating canonical Wnt pathway using folate and inositol | |
| TW201443075A (en) | Extraction and purification method for enzymolysis product of Spirulina Phycocyanin | |
| Dabb | Investigating the Effect of oCOm-21 on the NLRP3 Inflammasome in Cardiac Ischaemia Reperfusion Injury | |
| Musialowski | The role of endothelial glutamine synthetase in vascular tone and atherogenesis | |
| Popazova et al. | Molecular and Biochemical Mechanisms of Cardiomyopathy Development Following Prenatal Hypoxia—Focus on the NO System | |
| Iyer | A Novel Role for eNOS in Regulating Lymphatic Valve Development During Embryogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21785029 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16.03.2023) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21785029 Country of ref document: EP Kind code of ref document: A1 |